CareDx Inc. (CDNA) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
CareDx Inc. (CDNA) slipped -0.85% to $71.52 as options desks priced 56% call premium vs. 44% put protection around the $70 max-pain magnet. Solid 41% profit margin (-8% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
CareDx has been on a powerful multi‑year run, and the latest surge in transplant testing news has pushed the valuation conversation back to basics: its cash flows. With the stock now in a very different place to three ye
The precision medicine pioneer is helping to improve patient care.
October 30, 2026 gap list shows sharp opening gaps and session moves for gap-up stocks such as GDYN and gap-down stocks such as ATEC.
Testing volumes surged 51% as NavDx integration drove revenue and margin gains.
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
CareDx, Inc. (CDNA) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDTCompany ParticipantsNina DekaJohn Hanna - President, CEO & DirectorKeith Kennedy -...
BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $81 to $92.
Civeo shares surged 19.9% after earnings beat estimates and FY2026 sales guidance rose; other premarket movers included SLGB, HUBC and ATEC.
CareDx (NASDAQ:CDNA) reported third-quarter 2026 revenue growth of 39% as testing volumes increased, driven by its transplant business and the addition of Specialty Oncology testing following the July acquisition of Nave
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +13.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CDNA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CDNA. Explore sector supply chains on /butterfly.
Why CDNA Stock slipped -0.85% Today — RQD Quant Desk Flash. Solid 41% profit margin (-8% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.